---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-021600"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:45:57.223531+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Graphite Bio announces two abstracts accepted for ASH 2022 annual meeting

## Summary
- Abstract #5965 describes beta-globin gene replacement strategy for beta-thalassemia using UltraHDR platform.
- Abstract #3468 (poster) details single-cell RNA sequencing method to assess gene-editing outcomes in sickle cell disease.
- CEO Josh Lehrer notes initial proof-of-concept data for nula-cel (SCD therapy) expected mid-2023.
- Nula-cel is a first-in-human gene correction therapy; FDA granted Fast Track and Orphan Drug designations.
- ASH meeting takes place Dec 10-13, 2022 in New Orleans.

## SEC filing metadata
- accession: 0000950170-22-021600
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000095017022021600/0000950170-22-021600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000095017022021600/grph-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-021600
- JSON: https://secwatch.observer/filing/0000950170-22-021600.json
- Plain text: https://secwatch.observer/filing/0000950170-22-021600.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.